About Us About Us

Management Team

The drug development process is complex. Our management team offers deep expertise in all aspects of the process to drive products toward commercialization.


m_baker

Mark R. Baker

Chief Executive Officer

Mr. Baker joined the Company in 2005 as Senior Vice President & General Counsel and Secretary. In 2008, he was appointed Executive Vice President – Corporate, in 2009 became President, and has been CEO since March 2011. From 2003 to 2005, Mr. Baker was Chief Business Officer, Secretary and a director of New York Trans Harbor LLC, a privately-held ferry operation in New York City. From 1997 to 2001, he was Executive Vice President, Chief Legal Officer and Secretary of Continental Grain Company, a privately-held international agri-business and financial concern. Prior thereto, he was a partner and Co-Chairman of the Capital Markets Group of the New York law firm Dewey Ballantine. Mr. Baker has an A.B. degree from Columbia College and a J.D. from the Columbia University School of Law.


r_israel

Robert J. Israel M.D.

Executive Vice President, Medical Affairs

Dr. Israel has been with Progenics since 1994. He previously held oncology positions at Sandoz Pharmaceuticals Corporation and Schering-Plough Corporation. Dr. Israel is a licensed physician and is board certified in internal medicine and medical oncology. He received a B.A. in physics from Rutgers University and an M.D. from the University of Pennsylvania, and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center. Dr. Israel has been a consultant to the Solid Tumor Service at Sloan-Kettering.


Hagop

Hagop Youssoufian, M.Sc., M.D.

Executive Vice President, Research & Development

Dr. Youssoufian joined Progenics in 2013 as Executive Vice President, Research & Development. He has more than 12 years’ experience in senior roles in clinical and translational science at Bristol-Myers Squibb, Sanofi Aventis, ImClone and Ziopharm, where he led or supported the development of Sprycel, Taxotere, Elitek, and Erbitux. Before entering the pharmaceutical industry, and after training in Internal Medicine, Clinical Genetics, and Hematology-Oncology, he served on the faculties of Harvard Medical School and Baylor College of Medicine. He received a B.S. in biology from Boston College and M.Sc./M.D. from University of Massachusetts Medical School. He is an elected member of the American Society for Clinical Investigation and the author of over 100 publications.


n_ray

Nitya G. Ray Ph.D.

Senior Vice President, Manufacturing

Dr. Ray, Senior Vice President, Manufacturing, joined Progenics in 2001. Prior to joining Progenics, Dr. Ray served as Director of Bioprocess Development at Ortec International, and before that held positions of increasing responsibility at Hoffmann-La Roche in the areas of GMP Manufacturing and Process Development, ultimately as Research Leader, Biopharmaceuticals. Early in his career he developed process technology for biopharmaceutical manufacturing at Verax Corporation. Dr. Ray received an M.S. and Ph.D. in chemical and biochemical engineering from Rutgers University and a B.S. in chemical engineering from Jadavpur University, India.


v_wong

Vivien Wong Ph.D.

Senior Vice President, Operations and Portfolio Management

Dr. Wong currently serves as Senior Vice President, Operations and Portfolio Management. For three years prior to joining Progenics in 2007, Dr. Wong was Principal at Theritas Pharmaceutical Consultants. From 1989 to 2004, she held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. Dr. Wong has been a co-author on over 30 scientific articles for peer-reviewed journals. She received a B.Sc. in biology from the Mississippi University for Women, a Ph.D. in anatomy and neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in neurology at the Albert Einstein College of Medicine.


a_assumma

Ann Marie Assumma M.S.

Vice President, Regulatory Affairs

Ms. Assumma joined Progenics in 2004 and currently serves as Vice President, Regulatory Affairs. She has over 30 years’ experience in the pharmaceutical industry and regulatory affairs at companies including Dov Pharmaceuticals, Emisphere Technologies, Bayer and American Cyanamid. Ms. Assumma earned her M.S. in pharmacology from New York Medical College and a B.S. in biology from Fordham University.


Angelo Lovallo

Angelo Lovallo

Vice President, Finance and Treasurer

Mr. Lovallo was appointed Treasurer in 2011 and Vice President, Finance this year.  Before joining Progenics in 2008, he held Vice President, Financial Reporting positions at MBIA Inc. from 2004 to 2008 and AllianceBernstein from 1998 to 2004. Earlier in his career, he was in accounting policy at Salomon Smith Barney and a senior manager at KPMG LLP. He received a B.B.A. in public accounting from Hofstra University and is a Certified Public Accountant.


Jim-Garrison

James Garrison

Head of Business Development and Commercial Strategy

Mr. Garrison joined Progenics in 2012 to lead business development and commercial efforts. In this role, he is responsible for identifying and pursuing strategic business opportunities, including potential company and product acquisitions.

Prior to joining Progenics, Mr. Garrison was Vice President of Business Development for Ferring Pharmaceuticals, a global pharmaceutical company with a strategic focus in women’s health, urology, orthopedics and gastroenterology. Earlier in his career, Mr. Garrison held senior business development positions at Vyteris, Becton Dickinson and Zambon, an Italian pharmaceutical and chemical company.

Mr. Garrison received his undergraduate degree from Rhode Island College, an MLIS from Rutgers University and a master’s degree in business administration from Seton Hall University.